Last updated: May 25, 2026
INVEGA supply chains typically split into (1) paliperidone API sourcing and (2) finished-dose manufacturing for INVEGA (oral), INVEGA SUSTENNA (1-month injectable), INVEGA TRINZA (3-month injectable), and INVEGA HAFYERA (6-month injectable). The dominant commercial suppliers are the companies that manufacture Janssen’s long-acting injectable (LAI) formulations and their sterile/aseptic delivery systems, while API is sourced from specialized chemical manufacturers supplying paliperidone-grade intermediates and API.
No complete, product-by-product supplier roster for “INVEGA” can be stated from the information provided in this prompt alone.
Which companies supply INVEGA (paliperidone) finished doses to the US market?
Finished-dose “INVEGA” supply depends on whether the query is interpreted as Janssen’s oral extended-release tablet product, or as the broader paliperidone LAI franchise commonly grouped under “INVEGA.” Each product line has distinct manufacturing sites and controls due to different dosage forms (solid oral vs. sterile depot injections).
Are INVEGA and INVEGA SUSTENNA supplied by the same manufacturers?
Not reliably. Oral extended-release and LAI sterile suspensions usually have different CMOs and different inspection histories due to:
- Sterile manufacturing and depot formulation controls for LAIs (aseptic processing, filling, lyophilization or suspension processing depending on product design)
- Different regulatory expectations for particulate control, container closure integrity, and lot release testing for injectables
Where do finished-dose manufacturers show up in the regulatory record?
US FDA labels and manufacturing sections typically list the manufacturer or their parent, while site-level information is often reflected in:
- FDA CDER drug product labeling (manufacturing and testing statements)
- FDA facility registrations in public databases
- Inspection history (when publicly accessible)
- NDA/BLA chemistry and manufacturing section approvals (not always publicly enumerated by supplier name)
Who supplies paliperidone API for INVEGA?
Paliperidone API is produced through multi-step synthetic routes that require controlled impurity profiles and robust solvent recovery and crystallization controls. API suppliers for paliperidone are generally dedicated chemical manufacturers that provide an API meeting Janssen’s specifications.
What types of firms provide paliperidone API?
- API chemical synthesis manufacturers with GMP experience in antipsychotics
- Multi-purpose CMOs producing niche central nervous system (CNS) APIs
- Firms that sell to branded manufacturers under long-term supply agreements
Do API suppliers differ by country or by INVEGA product?
Yes. Supply agreements often vary by:
- Contract term and capacity availability
- Regulatory approvals for specific manufacturing sites
- Changes in sourcing due to process validation, inspections, and supply continuity planning
What is the supplier structure for INVEGA SUSTENNA, TRINZA, and HAFYERA?
The paliperidone LAI products are more complex supply chain programs than oral tablets, because the products require:
- Sterile filling and controlled particle size for depot suspensions
- Long-term stability management under temperature excursions and distribution stresses
- Tight lot-to-lot consistency for drug delivery kinetics
How do LAI suppliers typically break out in practice?
Usually into:
- API supplier to Janssen (or to a sub-manufacturer)
- Drug product CMO for sterile manufacturing and filling
- Secondary packaging and distribution preparation
Which supply bottlenecks drive LAI production risk?
Common LAI risk points include:
- Sterile filling line availability
- Primary container supply (syringes, vial components, stoppers, seals)
- Raw material lead times for depot formulation excipients
- Quality system alignment and deviation/lab capacity during surge demand
How does supplier dependency affect INVEGA availability during shortages?
Supplier concentration can amplify availability risk. If a single finished-dose site or sterile filling line is offline, production may pause even if API supply is available. For LAIs, depot formulation readiness and sterile release testing can become the pacing item.
What supply indicators matter for INVEGA continuity?
- FDA drug shortage notifications (when they occur)
- Batch release timing and lot disposition cadence
- Inspection outcomes and remediation timelines at manufacturing sites
- Container supply constraints for injectables
How does contract manufacturing relate to INVEGA IP and regulatory compliance?
Even when the supplier name changes, the regulatory compliance burden stays with the approved manufacturing process and validated control strategy. Manufacturing changes can trigger:
- Comparability assessments
- Updated CMC submissions
- Facility-specific validation runs and inspection readiness
Do supplier substitutions trigger FDA CMC filings?
Often yes for significant changes, depending on:
- Change scale (equipment, process parameters, formulation site, sterilization step)
- Whether the change is within an approved “change management protocol”
- Whether the change affects critical quality attributes
Key Takeaways
- “INVEGA” supplier information must be segmented by dosage form: oral extended-release vs. paliperidone LAI injectables.
- LAI products rely on sterile depot formulation and filling capacity, which drives a different supplier map than oral manufacturing.
- API sourcing is typically provided by specialized chemical manufacturers under long-term GMP supply agreements, while finished doses are produced by sterile drug product CMOs and Janssen’s controlled sites.
- Without a specific product target (INVEGA vs. SUSTENNA/TRINZA/HAFYERA) and a source basis (FDA label manufacturing section, facility registration record, or Orange Book/NDA CMC listing), a complete supplier roster cannot be stated accurately.
FAQs
- Who makes INVEGA (paliperidone) extended-release tablets in the US?
- Which companies fill and package INVEGA SUSTENNA syringes?
- What are the typical API and excipient sourcing patterns for paliperidone LAIs?
- How do manufacturing-site changes for paliperidone products show up in FDA documentation?
- What are the main supply-chain constraints that lead to paliperidone LAI shortages?
References
- FDA. “Drug Shortages.” US Food and Drug Administration. (Accessed 2026-05-26).
- FDA. “Drug Label Information (DailyMed).” US Food and Drug Administration. (Accessed 2026-05-26).
